By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

BioMarin Pharmaceutical Inc. 

105 Digital Drive

Novato  California  94949  U.S.A.
Phone: 415-506-6700 Fax: 415-382-7427


SEARCH JOBS

At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored.

BioMarin offers a friendly, fast-paced, collegial environment where success is measured by both the individual and collective efforts of hundreds of talented scientists, business professionals, technical specialists and experts in a variety of fields from sales and marketing, to finance, to manufacturing, to clinical and regulatory operations.

BioMarin is growing rapidly to support the development and global commercialization of breakthrough drugs to treat rare genetic diseases. The company’s product portfolio comprises six approved products and multiple clinical and pre-clinical product candidates.

You can make it happen at BioMarin, where the unique combination of big-company success in a small-company environment provides unparalleled opportunity for individual contributions and growth.




Key Statistics


Email: ir@bmrn.com
Ownership: Public

Web Site: BioMarin
Employees: 358
Symbol: BMRN
 









Company News
FDA Not Currently Planning To Hold Advisory Committee Meeting For BioMarin (BMRN)'s Pegvaliase Biologics License Application (BLA) 9/15/2017 8:00:18 AM
BioMarin (BMRN) Presents Interim Data Of Phase I/II Study Of BMN 250 For Treatment Of Sanfilippo B Syndrome (MPS IIIB) At 13th International Congress Of Inborn Errors Of Metabolism (ICIEM) 2017 9/6/2017 9:56:01 AM
FDA Accepts BioMarin (BMRN)'s Pegvaliase Biologics License Application (BLA) And Grants Priority Review Designation 8/30/2017 6:34:27 AM
BioMarin (BMRN) Announces Exercise In Full Of Underwriters' Option To Purchase Additional 0.599% Senior Subordinated Convertible Notes Due 2024 8/24/2017 7:05:00 AM
Bay Area’s BioMarin (BMRN) Expands With The World's “First and Largest” Gene Therapy Manufacturing Plant 8/8/2017 9:36:20 AM
BioMarin (BMRN) Announces Offering Of $450 Million Of Senior Subordinated Convertible Notes Due 2024 8/8/2017 9:18:29 AM
BioMarin (BMRN) Announces Second Quarter 2017 Financial Results 8/3/2017 12:18:45 PM
BioMarin (BMRN) Announces Plans To Progress Both The 6e13vg/Kg And 4e13 Vg/Kg Doses Of BMN 270, Its Investigational Gene Therapy For Hemophilia A, Into Phase III Studies 8/3/2017 8:18:21 AM
BioMarin (BMRN) To Host Second Quarter 2017 Financial Results Conference Call And Webcast On Wednesday, August 2 At 4:30pm ET 8/1/2017 2:02:16 PM
BioMarin (BMRN) To Host Second Quarter 2017 Financial Results Conference Call And Webcast On Wednesday, August 2 At 4:30pm ET 7/19/2017 9:29:20 AM
12345678910...
//-->